SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc.
NNVC 2.010+21.1%Nov 3 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Straynut who wrote (12722)4/15/2020 7:32:16 AM
From: old 'n cranky1 Recommendation

Recommended By
Savant

   of 12871
 
In addition to HIV, avian influenza, and Ebola, the company has previously worked on nanoviricides for the MERS coronavirus that first emerged in 2014.



Yet no NanoViricides drug has ever undergone a clinical trial and successfully treated a single patient for any of those things. Their mention alone is shameful.

One thing that their mention should highlight for thinking readers is the likelihood of NNVC's success in developing a COVID-19 treatment....it's not likely at all.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News